A web-based survey was designed in which 72 neurology residents and 88 MS specialists from the USA and Canada partook. MS atypical syndromes that were incorrectly identified as typical by residents and MS specialists, respectively, were complete transverse myelopathy (by 35% and 15%); intractable vomiting/nausea/hiccups (20% and 5%); and bilateral optic neuritis/unilateral optic neuritis with poor visual recovery (17% and 10%). āTouch or abuttingā the ventricle criterion for periventricular lesions was correctly identified by 38% of residents and 61% of MS specialists; ājuxtacorticalā by 19% and 54%. Optic nerve involvement was incorrectly seen as a region that fulfils the criterion of MRI dissemination in space by 31% of residents and 26% of MS specialists. Subcortical white matter was incorrectly identified as a region that fulfils MRI dissemination in space by 11% and 18%. A case of radiologically isolated syndrome (RIS) was incorrectly identified as justifying the diagnosis MS by 48% and 12%. Nonspecific historical visual symptoms were incorrectly seen as fulfilling the criterion of dissemination in time by 75% of residents and 49% of MS specialists. Non-specific historical sensory and coordination symptoms were considered to fulfil dissemination in time by 88% and 65%.
1. Solomon A, et al. AA 2019, S6.001.
Posted on
Previous Article
« Galcanezumab reduces cluster headache frequency Next Article
Efficacy, tolerability, and safety of ubrogepant confirmed »
« Galcanezumab reduces cluster headache frequency Next Article
Efficacy, tolerability, and safety of ubrogepant confirmed »
Table of Contents: AAN 2019
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer's Disease and other Dementias
Amyloid PET in cognitively impaired patients
Tight blood pressure control lowers risk of mild cognitive impairment
Epilepsy
Headache and Migraine
Multiple Sclerosis and NMOSD
Immune tolerance by peptide-loaded tolerogenic dendritic cells
Biotin, ocrelizumab, and ibudilast in progressive MS
No increased MS relapse risk postpartum
Neuromuscular Disorders
First-ever effective and safe treatment of CMT1A
Parkinsonās Disease and other Movement Disorders
Leukaemia and hypertension therapies tested in Parkinson’s disease
Stroke
Miscellaneous
Possibly lifesaving therapy in refractory PML
New AAN guideline for treating Tourette syndrome
Subspecialty teleneurology: feasible and highly valued
Related Articles
July 30, 2019
New formulation of rimegepant: fast onset of action
July 30, 2019
First-ever effective and safe treatment of CMT1A
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com